Comparison of effects of valsartan and amlodipine on cognitive functions and auditory P300 event-related potentials in elderly hypertensive patients

Clinical Neuropharmacology

Volumn 37, Issue 5, 2014, Pages 129-132

  Katada, Eiichi ^a   Uematsu, Norihiko ^a   Takuma, Yuko ^a   Matsukawa, Noriyuki ^b  

^a Nagoya City University West Medical Center   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Amlodipine; Auditory P300 event related potentials; Cognitive function; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; VALSARTAN; ANTIHYPERTENSIVE AGENT; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COGNITION; DRUG EFFECT; ESSENTIAL HYPERTENSION; EVOKED AUDITORY RESPONSE; FEMALE; GERIATRICS; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; VERBAL BEHAVIOR; VERY ELDERLY; WORD LIST RECALL; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; EVENT RELATED POTENTIAL; HEART RATE;

AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COGNITION; EVENT-RELATED POTENTIALS, P300; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TETRAZOLES; VALINE;

EID: 84913601555     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000042     Document Type: Article

References (14)

1. von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006;326:599-616.
2. Oprisiu-Fournier AFR, Serot JM, Godefroy O, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009;9: 1413-1431.
3. Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004;59:863-868.
4. Ortiz AT, Perez-Serrano JM, Zaglul ZC, et al. P300 clinical utility in major depression. Actas Esp Psiquiatr 2002;30:1-6.
5. Katada E, Sato K, Sawaki A, et al. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 2003;16:39-43.
6. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental state" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
7. Tranel D. Neuropsychological assessment. Psychiatr Clin North Am 1992; 15:283-299.
8. Morris JC,Mohs RC, Rogers H, et al. Consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
9. Mohs RC, Kim Y, Johus CA. Assessing change in Alzheimer's disease: memory and language tests. In: Poon LW, ed. Handbook for Clinical Memory Assessment of Older Adults. Washington, DC: American Psychological Association, 1986:149-155.
10. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
11. Helmy MS. Angiotensin receptor blockers: how important is selectivity? AJH 2002;15:1006-1014.
12. Barnes JM, Barns NM, Costall B, et al. Angiotensin II inhibits the release of (3H) acetylcholine from the rat entorhinal cortex in vivo. Brain Res 1989;492:136-143.
13. Okuyama S, Sakagawa T, Inagami T. Role of the angiotensin II type 2 receptor in the mouse central nervous system. Jpn J Pharmacol 1999;81:259-263.
14. Wright JW, Stubley LA, Pederson ES, et al. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999;19:3952-3961.